利拉鲁肽对乳腺癌合并糖尿病患者血清肿瘤标志物及乳腺组织中凋亡相关因子水平的影响

Effects of Liraglutide on Serum Tumor Markers and Apoptosis-Related Molecular Levels in Breast Tissues of Patients with Breast Cancer and Diabetes

目的探究利拉鲁肽对乳腺癌合并糖尿病患者血清肿瘤标志物及乳腺组织中凋亡相关分子水平的影响。方法选择我院收治的乳腺癌合并糖尿病患者102例为研究对象,随机分为对照组和观察组,各51例。对照组患者接受常规抗肿瘤药物及胰岛素治疗,观察组在对照组的基础上联合利拉鲁肽治疗。分析两组患者的近期疗效,比较两组患者治疗前、后血糖指标[空腹血糖(FPG),2 h餐后血糖(2hPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)]水平、血清肿瘤标志物[癌胚抗原(CEA)、肿瘤相关糖蛋白抗原153(CA153)]水平及乳腺组织中凋亡相关因子[诱捕受体3(DcR3)、Livin、Survivin、半胱天冬酶-3(Caspase-3)、环氧合酶-2(COX-2)]水平。统计治疗过程两组患者不良反应的发生情况。结果观察组患者治疗总有效率及临床获益率均明显高于对照组(P<0.05)。治疗后,观察组FPG、2hPG、HbA1c、FINS水平及血清CEA、CA153水平均明显低于对照组(P<0.05),乳腺组织中DcR3、Livin、Survivin、Caspase-3、COX-2水平均显著低于对照组(P<0.05)。治疗过程中两组患者均未发生明显不良反应。结论利拉鲁肽治疗乳腺癌合并糖尿病患者能有效降低血清肿瘤标志物及乳腺组织中凋亡相关因子水平,具有较好的近期疗效及较高的安全性。

Objective To investigate the effects of liraglutide on serum tumor markers and apoptosis-related molecular levels in breast tissue of patients with breast cancer and diabetes.Methods A total of 102 patients with breast cancer and diabetes were randomly divided into control group and observation group,51 cases in each group.All patients were given routine anti-tumor drugs and insulin treatment.Those in observation group were additionally given liraglutide.The short-term curative effects of both groups were analyzed.The levels of blood glucose indexes such as fasting plasma glucose(FPG),2 h postprandial glucose(2hPG),glycosylated hemoglobin(HbA1c)and fasting insulin(FINS),serum tumor markers such as serum carcinoembryonic antigen(CEA),cancer-associated glycoprotein antigen 153(CA-153),and apoptosis-related molecules in breast tissue like decoy receptor 3(DcR3),Livin,Survivin,caspase-3,and cyclooxygenase-2(COX-2)before and after treatment were compared between the two groups.The occurrence of adverse reactions in both groups during treatment period was statistically analyzed.Results After treatment,the total effective rate and clinical benefit rate of the observation group were significantly higher than those of the control group(P<0.05).The levels of FPG,2hPG,HbA1c,FINS,serum CEA and CA-153 of the observation group were significantly lower than those of the control group(P<0.05).The levels of DcR3,Livin,Survivin,Caspase-3 and COX-2 in breast tissues of observation group were also lower than those of control group(P<0.05).No significant adverse reactions were observed in either group during treatment period.Conclusion Liraglutide could effectively reduce levels of serum tumor markers and apoptosis-related molecules in breast tissues of patients with breast cancer and diabetes.It could achieve good short-term curative effect and relatively higher safety.